Valneva Submits Chikungunya Vaccine for Accelerated EMA Assessment

VLA1553 is currently the first and only chikungunya vaccine candidate worldwide for which regulatory review processes are underway. A Biologic License Appl...

October 26, 2023 | Thursday | News
ENHERTU® First HER2 Therapy for HER2 Mutant Advanced NSCLC Approved in EU

ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with advanced non-s...

October 24, 2023 | Tuesday | News
EORTC and Menarini Group Initiate Early-Stage Breast Cancer Trial

Trial expected to screen more than 1900 early-stage breast cancer patients at 120+ sites in 12 countries across Europe, commencing in...

October 23, 2023 | Monday | News
Adiso Therapeutics Reports Positive Phase 1b Results for ADS051 in Treating Moderate-to-Severe Ulcerative Colitis

ADS051 was safe and well-tolerated at all doses with no safety signal observed Clinical remission was achieved in 22% of patients after only 28 days on dr...

October 23, 2023 | Monday | News
Japanese Startup Buzzreach Becomes First to Join U.S. Decentralized Trials & Research Alliance

Buzzreach is engaged in the development of a clinical trial and clinical research platform business that leverages the power of technology to address the c...

October 20, 2023 | Friday | News
LG Chem Initiates Phase 2 Trials for Novel MC4R Agonist LB54640 in Rare Genetic Obesity

LG Chem announces initiation of two phase 2 clinical trials in patients with defects in MC4R pathway causing severe obesity and hyperphagia. - LG Chem cont...

October 18, 2023 | Wednesday | News
Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)

Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause More than half of women ages 40 to 64 wor...

October 16, 2023 | Monday | News
Samsung Bioepis Presents Phase 1 and 3 Clinical Results for SB16 Biosimilar to Prolia at ASBMR 2023

Phase 1 study for SB16, proposed biosimilar to Prolia, demonstrates pharmacokinetic (PK) bioequivalence between SB16, EU-sourced denosumab, and US-source...

October 16, 2023 | Monday | News
Kintor Pharma Gets Approval for Phase II IPF Treatment Trial in China

IPF is a chronic, progressive fibrosing interstitial pneumonia and one of the most fatal interstitial pneumonias. The incidence of IPF is high, but due to ...

October 12, 2023 | Thursday | News
SOTIO Doses First Patients in CLAUDIO-01 Study for First-Line Gastric and Pancreatic Cancer

Combination arms to treat patients in first-line setting, providing valuable insights on future development potential for this patient population Phase ...

October 12, 2023 | Thursday | News
Novo Nordisk Halts Weekly Semaglutide Kidney Trial FLOW Due to Interim Analysis

The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee (DMC) concluding that the results from an interi...

October 11, 2023 | Wednesday | News
Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487

Hansa Biopharma, "Hansa", a pioneer in enzyme technology for rare immunological conditions,  announced high-level results from NICE-01, the first-in-h...

October 10, 2023 | Tuesday | News
Medidata and the National Cancer Institute Extend 15-Year Partnership for an Additional Five Years

-Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry,  announced an extension ...

October 05, 2023 | Thursday | News
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...

October 05, 2023 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close